Optimizing treatment for the prevention of pre-eclampsia/eclampsia in Nepal

Journal Article
(Published December, 2016)
Feldhaus, I. (Author),
LaFevre, A.E. (Author),
Rai, C. (Author),
Bhattarai, J. (Author),
Russo, D. (Author),
Rawlins, B. (Author),
Chaudhary, P. (Author),
Thapa, K. (Author)
0 votes
Calcium supplementation for pregnant mothers for prevention of PE/E provided with MgSO4 for treatment holds promise for the cost-effective reduction of maternal and neonatal morbidity and mortality associated with PE/E. The findings of this study compare favorably with other low-cost, high priority interventions recommended for South Asia. The costs to start-up calcium introduction in addition to MgSO4 were $44,804, while the costs to support ongoing program implementation were $72,852. Collectively, these values correspond to a program cost per person per year of $0.44. The calcium program corresponded to a societal cost per DALY averted of $25.33 ($25.22-29.50) when compared against MgSO4 treatment. Primary cost drivers included rate for facility delivery, costs associated with hospitalization, and the probability of developing PE/E. The addition of calcium to the standard of care corresponds to slight increases in effect and cost, and has a 84% probability of cost-effectiveness above a WTP threshold of $40 USD when compared to the standard of care alone.

Downloads for this Resource

Feldhaus I, LeFevre AE, Rai C, Bhattarai J, Russo D, Rawlins B, et al. Optimizing treatment for the prevention of pre-eclampsia/eclampsia in Nepal: is calcium supplementation during pregnancy cost-effective? Cost Eff Resour Alloc. 2016;14:13.